placeholder

Product News

05.17.2013

Forest Laboratories, Inc (NYSE: FRX) today announced that they will present data related to aclidinium bromide and roflumilast at the American Thoracic Society (ATS) International Conference on May 17-22 in Philadelphia, PA. Seven posters, two poster discussion sessions and one late breaking abstract will be presented for aclidinium bromide. Roflumilast related data will be highlighted in four posters and three poster discussion sessions. more...

05.16.2013

Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA. Data on cariprazine, an investigational antipsychotic agent, provides details from Phase 3 trials for schizophrenia and acute mania in bipolar I disorder, as well as a long-term safety more...

05.14.2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2013 in Orlando, Fla., May 18 through May 21, 2013. Among the data highlighted will be two oral presentations: one providing insight into the GC-C/cGMP pathway in patients with IBS-C and another describing the effects of linaclotide on inhibiting visceral pain, more...

05.01.2013

Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair® (Genuair® outside the USA) inhaler.

more...
04.15.2013

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide, (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

more...
12.10.2012

Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) announced today that Tudorza™ Pressair™ (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States. Tudorza is a long-acting anticholinergic recently approved by the U.S. Food and Drug Administration (FDA) for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including more...

12.03.2012

Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar more...

11.28.2012

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd. (collectively,“Forest”) announced today that they have entered into settlement agreements with Alkem Laboratories, Ltd. ("Alkem"), Indchemie Health Specialties Pvt. Ltd. ("Indchemie"), and Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc.

more...
11.14.2012

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer’s type in the United States.

more...
10.01.2012

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2013 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2012. At 10:00 AM EDT, Forest will host a conference call where Elaine Hochberg, Executive Vice President, Sales & Marketing and Chief Commercial Officer, Frank Perier, Executive Vice President Finance & more...

09.26.2012

Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories today announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran was discovered by Pierre Fabre and jointly developed by Forest Laboratories and Pierre Fabre, under a more...

08.30.2012

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZESS™ (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

more...
08.30.2012

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESS™  at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 26759985. more...

07.23.2012

Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM.MC) announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

more...
06.01.2012

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, and Nabriva Therapeutics announced today that they have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Pursuant to the agreement, Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months. more...

05.18.2012

Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA. Positive top-line results from the aclidinium pivotal double-blind placebo-controlled studies were first reported in 2011.

more...
05.04.2012

Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual Meeting scheduled May 5-9, 2012 in Philadelphia, PA. Data on cariprazine, an investigational antipsychotic agent, includes additional details from a Phase III trial for acute mania in bipolar I disorder and results from an open-label more...

04.25.2012

Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced additional positive results from a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD). Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD compared to placebo, as measured by the Montgomery-Asberg Depression Rating Scale - Clinician Rated ( more...

04.23.2012

CAMBRIDGE, Mass. and NEW YORK, April 23, 2012 (BUSINESS WIRE)— Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

more...
04.02.2012

Forest Laboratories, Inc. (NYSE: FRX) today announced that Forest Laboratories Holdings Limited (Forest), its wholly owned subsidiary, and Janssen Pharmaceutica NV (Janssen) entered into an agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic® (nebivolol), which is currently approved in the United States for the treatment of hypertension, thereby eliminating all future royalties. more...

03.14.2012

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced that Forest and Janssen Pharmaceutica NV have jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for infringement of U.S. Patent No. 6,545,040 (“the ‘040 patent”), relating to Forest’s BYSTOLIC® product. Forest licenses the ‘040 patent from Janssen. The ‘040 patent expires in more...

02.23.2012

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa. The pivotal clinical study of Colobreathe demonstrated the benefits and its ability more...

02.07.2012

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.

more...